RICHARD /CA/ MURRAY - 01 Feb 2022 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role
CEO and President, Director
Signature
/s/ Kim C. Drapkin, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
03 Feb 2022, 18:37:22 UTC
Previous filing
11 Jan 2022
Next filing
11 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Award $0 +87,500 +47% $0.000000 273,077 01 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 01 Feb 2022 Common Stock 175,000 $7.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest quarterly in 16 equal installments following January 1, 2022.